X
Xinxin Xu
Researcher at Children's Oncology Group
Publications - 14
Citations - 292
Xinxin Xu is an academic researcher from Children's Oncology Group. The author has contributed to research in topics: Medicine & Hazard ratio. The author has an hindex of 5, co-authored 8 publications receiving 98 citations.
Papers
More filters
Journal ArticleDOI
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial
Patrick A. Brown,Lingyun Ji,Xinxin Xu,Meenakshi Devidas,Laura E. Hogan,Michael J. Borowitz,Elizabeth A. Raetz,Gerhard Zugmaier,Elad Sharon,Melanie Brooke Bernhardt,Stephanie A. Terezakis,Lia Gore,James A. Whitlock,Michael A. Pulsipher,Stephen P. Hunger,Mignon L. Loh +15 more
TL;DR: In this article, a randomized phase 3 clinical trial was conducted by the Children's Oncology Group at 155 hospitals in the US, Canada, Australia, and New Zealand with enrollment from December 2014 to September 2019 and follow-up until September 30, 2020.
Journal ArticleDOI
A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331
Patrick A. Brown,Lingyun Ji,Xinxin Xu,Meenakshi Devidas,Laura Hogan,Michael J. Borowitz,Elizabeth A. Raetz,Gerhard Zugmaier,Elad Sharon,Lia Gore,James A. Whitlock,Michael A. Pulsipher,Stephen P. Hunger,Mignon L. Loh +13 more
TL;DR: Brown et al. as discussed by the authors showed that blinatumomab is superior to standard chemotherapy as post-reinduction consolidation prior to HSCT, resulting in fewer and less severe toxicities, higher rates of MRD response, greater likelihood of proceeding to HLCT and improved disease-free and overall survival.
Journal ArticleDOI
Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) study.
Susan R. Rheingold,Lingyun Ji,Xinxin Xu,Meenakshi Devidas,Patrick A. Brown,Lia Gore,Naomi J. Winick,William L. Carroll,Stephen P. Hunger,Elizabeth A. Raetz,Mignon L. Loh,Deepa Bhojwani +11 more
TL;DR: Survival of pediatric ALL patients now approaches 90%, but is historically poor for those who relapse, and overall survival has improved, according to the largest cohort assembled to date.
Journal ArticleDOI
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621
Maureen M. O'Brien,Lingyun Ji,Nirali N. Shah,Susan R. Rheingold,Deepa Bhojwani,C. Z. Yuan,Xinxin Xu,Joanna Yi,Andrew Harrison,Patrick O. Brown,Michael Horowitz,O. Militano,John A. Kairalla,Meenakshi Devidas,Elizabeth A. Raetz,Lia Gore,Mignon L. Loh +16 more
TL;DR: Inotuzumab ozogamicin is effective and well tolerated in heavily pretreated children and adolescents with R/R CD22-positive B-ALL and combined with chemotherapy is underway.
Journal ArticleDOI
Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group
Yousif Matloub,Karen R. Rabin,Lingyun Ji,Meenakshi Devidas,Johann Hitzler,Xinxin Xu,Bruce Bostrom,Linda C. Stork,Naomi J. Winick,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Nyla A. Heerema,Eileen Stonerock,William L. Carroll,Stephen P. Hunger,Paul S. Gaynon +15 more
TL;DR: IV methotrexate with strict escalation parameters, as given in this study, was well tolerated, although the mean total tolerated dose received was lower in patients with DS than in those without DS.